BLPH — Bellerophon Therapeutics Share Price
0.000.00%
Last trade - 00:00- $0.69m
- -$3.70m
- 20
- 81
- 37
- 43
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.18 | ||
| Price to Tang. Book | 0.18 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.12 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -296.4% | ||
| Return on Equity | -165.96% | ||
| Operating Margin | -195.66% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 5.64 | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company’s focus is to develop its nitric oxide therapy for patients with pulmonary hypertension (PH) using its delivery system, INOpulse. The Company’s INOpulse program is an extension of the technology used in hospitals to deliver continuous flow inhaled nitric oxide. INOpulse program is built on scientific and technical development for the therapeutic delivery of inhaled nitric oxide. It is also developing INOpulse for the treatment of patients with fibrotic interstitial lung disease (fILD), PH-Sarcoidosis, PH-chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension, and other pulmonary hypertension conditions. The Company’s subsidiaries include Bellerophon BCM LLC, Bellerophon Pulse Technologies LLC and Bellerophon Services, Inc.
Directors
- Naseem Amin CHM (59)
- Peter Fernandes CEO (66)
- Nicholas Laccona CFO
- Parag Shah VOP (43)
- Martin Dekker VPR (48)
- Amy Edmonds VAD (49)
- Scott Bruder IND (59)
- Mary Cloyd IND (66)
- Crispin Teufel IND (45)
- Theodore Wang IND (54)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- October 17th, 2013
- Public Since
- February 13th, 2015
- No. of Shareholders
- 155
- No. of Employees
- 18
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 12,232,648
- Address
- 184 Liberty Corner Road, Suite 302, WARREN, 07059
- Web
- http://www.bellerophon.com/
- Phone
- +1 9085744770
- Auditors
- KPMG LLP
Upcoming Events for BLPH
Q2 2024 Bellerophon Therapeutics Inc Earnings Release
Q3 2024 Bellerophon Therapeutics Inc Earnings Release
Similar to BLPH
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
What is the Bellerophon Therapeutics share price?
As of Today at 19:33 UTC, shares in Bellerophon Therapeutics are trading at $0.06. This share price information is delayed by 15 minutes.
How has the Bellerophon Therapeutics share price performed this year?
Shares in Bellerophon Therapeutics last closed at $0.06 and the price had moved by -91.91% over the past 365 days. In terms of relative price strength the Bellerophon Therapeutics share price has underperformed the S&P500 Index by -93.21% over the past year.
What are the analyst and broker recommendations for Bellerophon Therapeutics?
The overall consensus recommendation for Bellerophon Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Bellerophon Therapeutics dividend yield?
Bellerophon Therapeutics does not currently pay a dividend.
Does Bellerophon Therapeutics pay a dividend?
Bellerophon Therapeutics does not currently pay a dividend.
When does Bellerophon Therapeutics next pay dividends?
Bellerophon Therapeutics does not currently pay a dividend.
How do I buy Bellerophon Therapeutics shares?
To buy shares in Bellerophon Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Bellerophon Therapeutics?
As of the previous close price of $0.06, shares in Bellerophon Therapeutics had a market capitalisation of $0.69m.
Where are Bellerophon Therapeutics shares listed?
Here are the trading details for Bellerophon Therapeutics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: BLPH
What kind of share is Bellerophon Therapeutics?
Based on an overall assessment of its quality, value and momentum Bellerophon Therapeutics is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Bellerophon Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Bellerophon Therapeutics is $2.00. That is 3458.72% above the last closing price of $0.06.
Analysts covering Bellerophon Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.00 for the next financial year.
What is the trend in the Bellerophon Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bellerophon Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +45.41%.
As of the last closing price of $0.06, shares in Bellerophon Therapeutics were trading -47.21% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Bellerophon Therapeutics PE Ratio?
The Bellerophon Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.06.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Bellerophon Therapeutics?
Bellerophon Therapeutics' management team is headed by:
- Naseem Amin - CHM
- Peter Fernandes - CEO
- Nicholas Laccona - CFO
- Parag Shah - VOP
- Martin Dekker - VPR
- Amy Edmonds - VAD
- Scott Bruder - IND
- Mary Cloyd - IND
- Crispin Teufel - IND
- Theodore Wang - IND